Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Drug: SubQ Amivantamab with Lazertinib for EGFR-Mutated NSCLC
In the PALOMA-3 study, subcutaneous amivantamab-lazertinib showed noninferior efficacy to intravenous administration with improved safety and convenience. The subcutaneous route si
New Reference: Niraparib – Abiraterone for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
The addition of niraparib to abiraterone significantly improved progression-free survival in patients with HRR-deficient metastatic prostate cancer. Safety analysis showed higher r
New Protocol: Epcoritamab with Rituximab and Lenalidomide for Follicular Lymphoma
The EPCORE FL-1 trial demonstrated that epcoritamab combined with lenalidomide and rituximab significantly improved response rate and progression-free survival compared to lenalido
New Reference: Vorasidenib for IDH1/IDH2-Mutant Low-Grade Gliomas
In the phase 3 INDIGO trial, vorasidenib significantly improved progression-free survival and time to next intervention over placebo for IDH1/2-mutant glioma. The treatment reduced
New Protocol: Tucatinib with Trastuzumab Emtansine for her2-Positive Metastatic Breast Cancer
In the HER2CLIMB-02 trial, the addition of tucatinib to T-DM1 improved progression-free survival among patients with HER2-positive breast cancer, showing an increase from 7.4 to 9.
New Protocol: Periop Tislelizumab with Chemotherapy for Resectable NSCLC
The RATIONALE-315 trial demonstrated that peri-operative tislelizumab with chemotherapy significantly improved overall survival and event-free survival compared to chemotherapy alo
New Drug: Sacituzumab Tirumotecan for Advanced Urothelial Carcinoma
Sacituzumab Tirumotecan demonstrated promising antitumor activity in advanced urothelial carcinoma with an ORR of 31% and a mOS of 12.1 months. Safety profile was manageable with n
New Protocol: Preoperative PAXG for Pancreatic Cancer
Preoperative PAXG significantly improved event-free survival compared to mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma. PAXG demonstrated a fa
New Reference: Nivolumab with Ipilimumab for Non-Colorectal MSI-H/dMMR Tumors
The MOST-CIRCUIT trial showed that combined treatment with nivolumab and ipilimumab achieved a high objective response rate and prolonged progression-free survival in patients with
